evidence: After 4 weeks of treatment, all doses of AZD3199 had increased mean peak and trough FEV1 values compared with placebo, but no clear dose–response was observed (Figure 2);
intervention: AZD3199 (200, 400 or 800 μg o.d.)
comparator: placebo via Turbuhaler®
outcome: mean peak and trough forced expiratory volume in one second (FEV1) values